Solid-phase synthesis of hydroxyethylamine angiotensin analogues

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Peptide Synthesis

Background:

• Angiotensins II, III, and IV are key peptide hormones in the renin-angiotensin system.
• Enzymatic degradation limits the therapeutic efficacy of native angiotensin peptides.
• Developing stable analogues is crucial for therapeutic applications.

Purpose of the Study:

• To synthesize novel hydroxyethylamine analogues of angiotensins II, III, and IV.
• To evaluate the binding affinity of these analogues to angiotensin receptors.
• To assess the metabolic stability of the analogues against enzymatic degradation.

Main Methods:

• Solid-phase peptide synthesis was employed for analogue preparation.
• Alkylation with iodomethylketone derivatives followed by sodium borohydride reduction formed the hydroxyethylamine linkage.
• Binding assays using labeled angiotensins and bovine adrenal membranes were performed.
• Metabolic stability was tested using kidney homogenates and aminopeptidase M.

Main Results:

• Three hydroxyethylamine analogues of angiotensins II, III, and IV were successfully synthesized.
• The hydroxyethylamine amide bond replacement resulted in reduced binding affinity compared to native angiotensins.
• The synthesized analogues demonstrated substantially enhanced stability against enzymatic degradation.

Conclusions:

• Hydroxyethylamine modification offers a strategy to improve the metabolic stability of angiotensin analogues.
• While affinity is reduced, the enhanced stability may present therapeutic opportunities for angiotensin-related conditions.
• Further research is warranted to optimize these analogues for potential drug development.